https://doi.org/10.31288/oftalmolzh201414447

To the issue of prevention of acute vessel optic neuropathy

N. V. Konovalova, N. I. Naritsyna, T. M. Serebrina, A. L. Reznichenko

 SI «The Filatov Institute of Eye Diseases And Tissue Therapy NAMS of Ukraine», Odessa

Key words: ischemic optic neuropathy, Lutein, Zeaxanthin.

Vascular pathology of the eye is one of the leading causes of blindness. Diseases caused by circulatory disorders constitute 10—15 % of all eye diseases. 

Purpose — to examine the preventive effect of lutein and zeaxanthin on the basis of clinical examination of patients with chronic vascular pathology. The possibility of acute vascular neuropathy for example, 57 patients (114 eyes) with chronic ischemic neuropathy of the optic nerve that within 3 months of receiving lutein and zeaxanthin, the control group consisted of 35 patients (70 eyes) who received no prophylactic treatment and in 3 patients (3 eyes) occurred venous occlusion and arterial occlusion of the vessels of the optic nerve. 

Conclusions. Use of lutein and zeaxanthin is preventing the emergence and development of acute retinal vascular occlusion. Patients who did not receive prophylactic treatment (4,28 %). Getting the vascular occlusion optic nerve.

References

1.Alifanova TA, Alifanova TA, Zosimova YaO. The role of cardiovascular diseases in the formation of disabling ocular pathology. Proceedings of international scientific conference, dedicated to 100 anniversary of academician NA Pu-chkovskaya «Modern aspects of the clinic, diagnosis and treatment of eye dioseases». Odessa; 29- 30 May 2008.

2.Volosovets AP, Krivopustov SP, Morozov TS. Disturbance of microcirculation: relevance in pediatrics and prospects for treatment. Praktychna angiologiia. 2008;4:29-31. Russian.

3.Gromova OA, Kudrin AV. Neurochemistry of macro and microelements. New approaches to pharmacotherapy. M.; 2001. 272 p.

4.Guseva MP. «Lutein Complex for children» in eye diseases pediatric practice. Rossiiskaya pediatricheskaia oftalmologiia. 2007;1:9-14. Russian.

5.Zavgorodnya NG, Sarzhevska LE, Bezdenezhna OO, Bezugla OA, Zavgorodnya TS, Rudicheva OA. Eye ischemic syndrome, modern principles of diagnosis and treatment. Textbook. Zaporizhzhya. 2012. 248 p.

6.Kanski JJ. Diseases of the Ocular Fundus KaHCKii. Avetisov SE, editor. M.; 2008. 3153 p.

7.Libman ES, Shakhova YeV. Blindness and disability due to eye pathology in Russia. Vestn Oftalmol. 2006; 122(1): 33-40.

8.Morozov VI, Yakovlev AA. Pharmacotherapy of eye diseases. M.: Meditsina; 2004 512 p.

9.Nikiforov AS, Guseva MR. Neuroophthalmology. M.: GEOTAR-Media; 2008. 624 p.

10.Brown DM, Kaiser PK, Michels M. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N. Engl. J. Med. 2006;5:1432- 44.
Crossref

11.Carneiro AM. Arterial Thromboembolic Events in Patients with Exudative Age-Related Macular Degeneration Treated with Intravitreal Bevacizumab or Ranibizumab. Ophthalmologica. 2011;18:211-25.
Crossref   Pubmed

12.Gass JD. Stereoscopic Atlas of Macular Diseases: diagnosis and treatment. The C. V. Mosby Company. St.Louis.1987;1:69.